文献速递消化系统肿瘤

多西他赛对比紫杉醇治疗氟尿嘧啶和铂类难治性食管鳞癌的随机II期研究

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201.
PubMed 文献 · Eur J Cancer · 2021-07-24

本研究为随机选择设计II期试验,比较多西他赛(DTX)与紫杉醇(PTX)在氟尿嘧啶和铂类一线化疗难治的食管鳞癌(ESCC)患者中的疗效与安全性。结果显示PTX组OS、无进展生存期(PFS)和至治疗失败时间(TTF)均显著优于DTX组,且≥3级中性粒细胞减少和发热性中性粒细胞减少发生率更低。

要点

  • PTX组中位OS为8.8个月,显著长于DTX组的7.3个月(HR 0.62,P=0.047)。
  • PTX组中位PFS为4.4个月,显著优于DTX组的2.1个月(HR 0.49,P=0.002)。
  • DTX组≥3级中性粒细胞减少和发热性中性粒细胞减少发生率显著更高。

核心结论

  • 在氟尿嘧啶和铂类难治性ESCC患者中,PTX相比DTX显示出显著更好的疗效和更可控的毒性。

研究设计与样本

  • DTX组给药方案为70 mg/m2,每21天周期第1天;PTX组为100 mg/m2,每49天周期第1、8、15、22、29、36天给药。
  • 主要终点为OS,次要终点包括PFS、TTF、缓解率(RR)和安全性。

主要发现

  • PTX组中位OS为8.8个月,DTX组为7.3个月(HR 0.62,P=0.047)。
  • PTX组中位PFS为4.4个月,DTX组为2.1个月(HR 0.49,P=0.002)。
  • PTX组中位TTF为3.8个月,DTX组为2.1个月(HR 0.45,P<0.001)。
  • PTX组RR为25.6%,DTX组为7.7%(P=0.065)。
  • DTX组≥3级中性粒细胞减少(80% vs 28%)、白细胞减少(76% vs 28%)及发热性中性粒细胞减少(46% vs 0%,P<0.0001)发生率均高于PTX组。

临床怎么用

  • 对于氟尿嘧啶和铂类难治性ESCC患者,PTX可作为优于DTX的化疗选择,因其疗效更优且毒性更可控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no standard chemotherapy for esophageal squamous cell carcinoma (ESCC) refractory to first-line fluoropyrimidine- and platinum-based chemotherapy. We therefore performed a randomized, selection-design phase II trial to compare docetaxel (DTX) and paclitaxel (PTX) in this setting. PATIENTS AND METHODS: Eligible patients were randomly assigned to receive either DTX (70 mg/m2 on day 1 of each 21-day cycle) or PTX (100 mg/m2 on days 1, 8, 15, 22, 29 and 36 of each 49-day cycle). The primary end-point was overall survival (OS), and secondary end-points included progression-free survival (PFS), time to treatment failure (TTF), response rate (RR) and safety. RESULTS: Seventy-eight eligible patients (N = 39 in each group) were included for efficacy analysis. OS was significantly longer in the PTX group than in the DTX group (median, 8.8 versus 7.3 months; hazard ratio [HR], 0.62; P = 0.047). A significant benefit of PTX over DTX was also apparent in PFS (median, 4.4 versus 2.1 months; HR, 0.49; P = 0.002) and TTF (median, 3.8 versus 2.1 months; HR, 0.45; P < 0.001). RR (25.6% versus 7.7%, P = 0.065) were higher in the PTX group than in the DTX group. Compared to the PTX group, neutropenia (28% versus 80%) and leukopenia (28% versus 76%) of grade ≥3 as well as febrile neutropenia (0% vs. 46%, P < 0.0001) occurred more frequently in the DTX group. CONCLUSION: PTX showed a significantly better efficacy as well as a more manageable toxicity compared with DTX. CLINICAL TRIAL REGISTRATION: UMIN000007940.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yamamoto S, Kawakami H, Kii T, et al. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. Eur J Cancer. 2021. PMID: 34311300. doi:10.1016/j.ejca.2021.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。